Elafibranor phase 3 results. Nov 13, 2023 · Methods: In this multinational, phase 3, doub...

Elafibranor phase 3 results. Nov 13, 2023 · Methods: In this multinational, phase 3, double-blind, placebo-controlled trial, we randomly assigned (in a 2:1 ratio) patients with primary biliary cholangitis who had had an inadequate response to or unacceptable side effects with ursodeoxycholic acid to receive once-daily elafibranor, at a dose of 80 mg, or placebo. gov for published phase three trial data of second-line PBC therapies. May 11, 2020 · GENFIT: Announces Results from Interim Analysis of RESOLVE-IT Phase 3 Trial of Elafibranor in Adults with NASH and Fibrosis RESOLVE-IT Phase 3 of Elafibranor in NASH: Final Results of the Week 72 Interim Surrogate Efficacy Analysis AASLD 2020 Nov 11-16 METHODS: We conducted a systematic review of PubMed, Medline, and ClinicalTrials. S. Apr 25, 2025 · The ELMWOOD phase II study(NCT05627362) is a randomized, double-blind, placebo-controlled study which evaluated the safety and efficacy of elafibranor in treating PSC, a rare liver disease. Elafibranor is currently being evaluated in the clinical Phase 3 study RESOLVE-IT. May 11, 2020 · In parallel, we continue as planned with our NIS4TM and Phase 3 PBC (primary biliary cholangitis) programs, which are independent of our NASH program with elafibranor. Lille (France), Cambridge (Massachusetts, United States), May 11, 2020– GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced results from an interim analysis of the RESOLVE-IT Phase 3 trial evaluating once-daily, 120mg of elafibranor in adults with non-alcoholic Introduction Elafibranor significantly improved biomarkers of cholestasis at Week 52 in patients with primary biliary cholangitis (PBC) in the phase III ELATIVE® trial ([NCT04526665][1]). We would like to show you a description here but the site won’t allow us. Nov 13, 2023 · The results from ELATIVE provide compelling evidence that elafibranor has the potential to achieve this goal, with evidence of a highly significant treatment benefit that is associated with improved clinical outcomes,” said Dr Christopher Bowlus, Professor of Gastroenterology and Hepatology, University of California Davis, U. RESULTS: Four phase three clinical trial evaluating obeticholic acid, bezafibrate, seladelpar, and elafibranor, were identified. Elafibranor (Iqirvo, Ipsen) has activity against both peroxisome proliferator May 29, 2024 · To the Editor: Pruritus is a frequent symptom in patients with primary biliary cholangitis and has been related to a high plasma concentration of substances that are excreted in bile. Conducted over 12 weeks, the trial involved 68 patients who were randomized to receive either elafibranor (80 mg or 120 mg) or a placebo. Nov 13, 2023 · In this multinational, phase 3, double-blind, placebo-controlled trial, patients were randomly assigned (in a 2:1 ratio) to receive once-daily elafibranor, at a dose of 80 mg, or placebo. Methods Patients completing the ELATIVE® double-blind period (DBP) were eligible to enter the OLE receiving The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis. Feb 13, 2025 · SAN DIEGO—The peroxisome proliferator–activated receptor agonist elafibranor is predicted to increase transplant-free survival and reduce mortality over 15 years in patients with primary biliary cholangitis, according to a new analysis of data from the phase 3 ELATIVE trial presented at The Liver Meeting 2024. A phase 2B trial of a PPAR α/δ agonist elafibranor (Ela) showed histological improvement in those with NASH, high disease activity and F2/3 fibrosis. . We report up to 3-year interim results from the ongoing ELATIVE® open-label extension (OLE). When hepatoce We would like to show you a description here but the site won’t allow us. The promising results concerning both efficacy and safety of Elafibranor have encouraged further phase III trial (ELATIVE, NCT04526665) initiation at the end of 2020 with the aim to test long-term effect on cholestasis of elafibranor 80 mg daily vs placebo (Table 2). The safety profile of GFT505 from the completed clinical trials appears satisfactory with no indication of PPAR-g agonist effects such as edema or body weight gain. We here report the interim results of the Phase 3 RESOLVE-IT trial of Ela in this population. dfjoa pqamaa tdgvx aqtyi sxafq owtfm ijhahyor uvif djog snvj